IP Library Patent Application 13977766
Patent Application
App. No. 13/977,766

USE OF THE PHYTOCANNABINOID CANNABIDIOL (CBD) IN COMBINATION WITH A STANDARD ANTI-EPILEPTIC DRUG (SAED) IN THE TREATMENT OF EPILEPSY

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
13/977,766
Abstract

The invention relates to the use of cannabidiol (CBD), at a dose of greater than 300 mg/day, in combination with a standard anti-epileptic drug (SAED) which acts via sodium or calcium channels, for use in the treatment of epilepsy. The SAED is preferably one which•modifies low-threshold or transient neuronal calcium currents,or•reduces high-frequency neuronal firing and sodium-dependent action potentials and enhances GABA effects. Preferred SAEDs are ethosuximide and valproate.

Claims (14)

1 . A method for treating epilepsy comprising administering to a subject in need thereof cannabidiol (CBD), at a dose of greater than 300 mg/day, in combination with a standard anti-epileptic drug (SAED) which acts via sodium or calcium channels, for use in the treatment of epilepsy.

2 . (canceled)

3 . The method of claim 1 , wherein the SAED is a drug which:

modifies low-threshold or transient neuronal calcium currents, or

reduces high-frequency neuronal firing and sodium-dependent action potentials and enhances GABA effects.

4 . The method of claim 1 , wherein the SAED is selected from the group consisting of: ethosuximide and valproate.

5 . The method of claim 1 , wherein the type of epilepsy to be treated is generalised seizure or temporal lobe seizure.

6 . The method of claim 1 , wherein the type of epilepsy to be treated is refractory to existing medication.

7 . The method of claim 1 , wherein the CBD is used with one or more other therapeutically effective phytocannabinoids.

8 . The method of claim 7 , wherein the one or more other therapeutically effective phytocannabinoid is THCV and/or CBDV.

9 . The method of claim 1 , wherein the CBD is an isolated phytocannabinoid.

10 . The method of claim 1 , wherein the CBD is in the form of a botanical drug substance.

11 . (canceled)

12 . A combination product comprising cannabidiol (CBD), at a dose of greater than 300 mg/day, and a standard anti-epileptic drug (SAED) which acts via sodium or calcium channels.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 15, 2024
From: OTSUKA PHARMACEUTICALS CO., LTD.
To: GW PHARMA LIMITED
Reel/Frame 067416/0406 →
SECURITY AGREEMENT Recorded Jul 22, 2021
From: GW PHARMA LIMITED; GW RESEARCH LIMITED
To: U.S. BANK NATIONAL ASSOCIATION
Reel/Frame 056958/0493 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 10, 2013
From: WHALLEY, BEN; WILLIAMS, CLAIRE; STEPHENS, GARY
To: GW PHARMA LIMITED; OTSUKA PHARMACEUTICAL CO. LIMITED
Reel/Frame 030764/0341 →